CJC 1295 (with DAC)
CJC-1295 with DAC is a synthetic growth hormone-releasing hormone (GHRH) analog modified with a Drug Affinity Complex to extend its half-life significantly. It is studied for its ability to stimulate pulsatile growth hormone release and elevate IGF-1 levels in research models. Investigated in contexts of tissue recovery, body composition, and anti-aging research.
58,00 €
CJC 1295 (with DAC) - Long-Acting Growth Hormone Releasing Peptide
Description
CJC-1295 with DAC is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH), structurally modified with a Drug Affinity Complex (DAC) that binds to circulating albumin. This modification dramatically extends its plasma half-life from minutes to approximately 6-8 days, allowing sustained stimulation of the somatotropic axis from a single administration.
In research models, CJC-1295 with DAC has been observed to elevate baseline growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels through prolonged activation of pituitary somatotroph cells. Studies report amplified GH pulse amplitude without disrupting the natural pulsatile release pattern, along with dose-dependent increases in circulating IGF-1 that persist for extended periods following subcutaneous administration.
Beyond direct somatotropic stimulation, CJC-1295 with DAC is studied for its downstream influence on lean tissue accretion, lipolysis, collagen synthesis, and sleep-phase GH release. It is frequently paired with GH-releasing peptides such as Ipamorelin in stacked research protocols to model synergistic axis activation.
Formulated as a lyophilized powder for reconstitution and subcutaneous administration, CJC-1295 with DAC offers stable pharmacokinetics and infrequent dosing intervals suited to long-duration experimental designs.
Clinical Status:
CJC-1295 with DAC is a research peptide evaluated in animal models and limited early-phase human pharmacokinetic studies for GH-axis modulation, body composition, and metabolic parameters. It is not approved for medical use and remains restricted to experimental and laboratory research.
Evidence type:
Human RCT ☐ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory ☐
Mechanism of Action
CJC-1295 with DAC works by acting as a growth hormone-releasing hormone (GHRH) analog, binding to GHRH receptors on the anterior pituitary and stimulating pulsatile release of endogenous growth hormone. The attached Drug Affinity Complex (DAC) enables covalent binding to serum albumin, dramatically extending its half-life and producing sustained elevations in GH and downstream IGF-1 in research models.
Benefits
- Sustained Growth Hormone Elevation:
CJC-1295 with DAC has been extensively studied for its ability to produce prolonged elevations in growth hormone (GH) and insulin-like growth factor 1 (IGF-1). The Drug Affinity Complex (DAC) enables covalent binding to serum albumin, extending the peptide’s half-life to approximately 6-8 days. In research models, this sustained release has been observed to generate steady GH pulses without the sharp peaks typical of shorter analogs. - Enhanced Lean Body Mass Development:
Experimental studies have documented CJC-1295 with DAC’s influence on protein synthesis and muscle tissue accretion. Elevated GH and IGF-1 levels have been linked with increased nitrogen retention, myocyte proliferation, and improved anabolic signaling. This makes CJC-1295 a frequent subject of research into body composition modulation and skeletal muscle hypertrophy in preclinical models. - Adipose Tissue Reduction:
Research models have observed enhanced lipolysis following CJC-1295 with DAC administration, driven by sustained GH activity on adipocyte hormone-sensitive lipase. Reduction in visceral and subcutaneous fat depots has been reported alongside improvements in overall lipid profiles. This dual anabolic-lipolytic effect positions CJC-1295 as a key candidate in metabolic and body recomposition research. - Accelerated Tissue Repair and Recovery:
CJC-1295 with DAC has been investigated for its regenerative effects on connective tissue, tendons, and musculoskeletal structures. Elevated IGF-1 concentrations have been observed to stimulate fibroblast activity, collagen deposition, and satellite cell recruitment. In research settings, this pathway supports faster recovery from induced injury and improved structural integrity of repaired tissues. - Improved Sleep Architecture:
Experimental models have noted enhanced slow-wave sleep (SWS) patterns associated with GH-releasing peptides, including CJC-1295 with DAC. Since deep sleep is the primary window for endogenous GH secretion, sustained GH-axis stimulation appears to reinforce this cycle. Research subjects have shown improved sleep continuity and deeper restorative phases, of particular interest to studies on recovery and neuroendocrine regulation. - Bone Density and Mineralization Support:
Preclinical research has evaluated CJC-1295 with DAC’s role in osteoblast activation and bone matrix formation. Elevated GH and IGF-1 levels have been linked to increased calcium retention, collagen type I synthesis, and improved trabecular bone architecture. These findings make the peptide a subject of interest in age-related bone loss models and skeletal regeneration studies. - Skin Quality and Collagen Synthesis:
CJC-1295 with DAC has been observed to influence dermal collagen production and elastin remodeling in experimental settings. GH-mediated fibroblast stimulation supports extracellular matrix renewal, improving skin thickness and elasticity markers in animal models. This has drawn research attention toward its potential role in dermatological aging and regenerative skin protocols. - Metabolic Efficiency and Insulin Dynamics:
Studies have investigated CJC-1295 with DAC’s broader impact on glucose metabolism and energy homeostasis. While sustained GH elevation can transiently modulate insulin sensitivity, research models have shown adaptive metabolic responses over extended cycles, including improved substrate utilization and mitochondrial efficiency. These effects position the peptide as a valuable tool in endocrine and metabolic research.
Research Data
| Study / Model | Reported effect |
|---|---|
| Healthy adult human PK study (single SC dose) | ↑ mean plasma GH levels 2–10 fold for up to 6 days; ↑ IGF-1 by 1.5–3 fold for 9–11 days |
| Repeated weekly dosing in humans | Sustained ↑ IGF-1 across multiple weeks; half-life extended to ~5.8–8.1 days via DAC-albumin binding |
| Rat pituitary cell cultures | Selective activation of GHRH receptor; pulsatile GH release preserved without desensitization |
| Aged rodent models | Restoration of GH pulse amplitude; ↑ lean mass and ↓ visceral adiposity over multi-week dosing |
| Growth hormone-deficient animal models | Normalization of IGF-1 levels; improved somatic growth markers |
| In vitro GHRH-R binding assays | High-affinity, prolonged receptor engagement compared to native GHRH (~30 min half-life) |
Stack Suggestions
CJC 1295 (with DAC) is often combined in research with:
- CJC 1295 (with DAC) + Ipamorelin → Amplifies GH pulse amplitude while preserving natural pulsatility and minimizing cortisol impact.
- CJC 1295 (with DAC) + BPC-157 → Combines sustained GH elevation with tissue-repair signaling for regenerative research models.
- CJC 1295 (with DAC) + Tesamorelin → Explores complementary GHRH pathway activation for lipolysis and body composition studies.
- CJC 1295 (with DAC) + MK-677 → Investigated for compounded IGF-1 elevation via dual GHRH and ghrelin-receptor stimulation.
- CJC 1295 (with DAC) + Hexarelin → Studied for synergistic GH secretagogue activity in short-cycle experimental protocols.
⚠ Stacks are for experimental design only; not safety or efficacy guidance.
Pen Dosage Chart
| CJC 1295 (with DAC) Pen 5 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 2.5 mg/mL |
| Click-to-Dose | 1 click = 0.025 mg |
| Example(s) | 10 clicks = 0.25 mg |
Dosage & Protocols Variations
Standard Research Protocol
- Dose: 1 – 2 mg
- Duration: 8 – 12 weeks
- Frequency: Once weekly
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Baseline GH/IGF-1 elevation for general research models on recovery and body composition.
Therapeutic Research Protocol
- Dose: 2 mg
- Duration: 12 – 16 weeks
- Frequency: Twice weekly (split dosing)
- Cycle Interval: 4 – 6 weeks off before repeating
- Goal / Description: Sustained GH pulse amplification for tissue repair and metabolic research endpoints.
Biohacker Protocol (experimental)
- Dose: 0.5 mg
- Duration: Continuous
- Frequency: Every 5 – 7 days
- Cycle Interval: Ongoing microdose model
- Goal / Description: Low-dose continuous exposure studied for longevity and sleep-quality parameters.
Stacked Protocol (CJC-1295 DAC + Ipamorelin)
- Dose: 1 – 2 mg CJC-1295 DAC + 200 – 300 mcg Ipamorelin
- Duration: 8 – 12 weeks
- Frequency: CJC weekly; Ipamorelin daily
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Combined tonic and pulsatile GH stimulation for synergistic anabolic and recovery models.
Possible Side Effects
CJC-1295 with DAC is generally well-tolerated in preclinical and limited human research studies.
Reported side effects are typically mild and transient:
- Localized redness, itching, or irritation at the injection site.
- Transient flushing or warmth shortly after administration.
- Mild headache or dizziness during initial dosing.
- Temporary water retention or tingling in extremities.
- Elevated fasting glucose or reduced insulin sensitivity with prolonged use.
No evidence of serious hepatic, cardiovascular, or endocrine adverse effects has been observed in available research data.
Product Attributes
- CAS #: 863288-34-0
- Molecular Formula: C165H269N47O46
- Sequence (AA): YADAIFTQSYRKVLAQLSARKLLQDIMSR
- Molecular Weight: 3647.2 g/mol
- PubChem CID: 91971820
- Half-Life: ~6-8 days
- Synonyms: CJC-1295 DAC, Drug Affinity Complex CJC-1295, GRF (1-29) analog with DAC, Modified GRF 1-29 with DAC
- Type: Synthetic research peptide (long-acting GHRH analog with albumin-binding DAC)
- Research Focus: Growth Hormone & IGF-1 Axis, Recovery & Performance, Longevity & Anti-Aging
Scientific References
- Sustained ghrelin receptor activity by CJC-1295, a long-acting GHRH analog Human RCT | Animal
- Long-acting GHRH analog CJC-1295 elicits sustained elevations in growth hormone and IGF-I Human RCT
- Effects of CJC-1295 on GH secretion in adult men Human RCT
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 Human RCT
- Drug Affinity Complex (DAC) technology for sustained GHRH bioactivity In vitro | Animal
- Growth hormone-releasing hormone analogs and their applications in metabolic research Observational | Animal
- GHRH analogs: mechanism, effects, and research overview Observational | Animal | In vitro
- GHRH and its analogues: therapeutic potential in aging and body composition Human RCT | Animal
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 8°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
